AAPL288.37+6.63 (+2.35%) ▲|ABBV252.55-1.76 (-0.69%) ▼|ABT91.62-1.09 (-1.18%) ▼|ACN123.89-0.85 (-0.68%) ▼|ADBE202.40-4.04 (-1.95%) ▼|AMAT730.21+35.57 (+5.12%) ▲|AMD572.95+33.46 (+6.20%) ▲|AMGN359.32-1.23 (-0.34%) ▼|AMT164.00-4.67 (-2.77%) ▼|AMZN239.47-0.67 (-0.28%) ▼|AVGO375.32+2.87 (+0.77%) ▲|AXP337.93-2.95 (-0.87%) ▼|BA216.73+2.04 (+0.95%) ▲|BAC57.02-0.87 (-1.49%) ▼|BKNG179.97-2.44 (-1.34%) ▼|BLK961.93+11.76 (+1.24%) ▲|BMY57.76-0.81 (-1.37%) ▼|BNY144.96+1.16 (+0.81%) ▲|BRK-B496.56+0.56 (+0.11%) ▲|C140.00-2.49 (-1.75%) ▼|CAT1,063.07+29.88 (+2.89%) ▲|CL91.95-0.46 (-0.49%) ▼|CMCSA24.54+0.32 (+1.30%) ▲|COF200.47-1.81 (-0.89%) ▼|COP104.36+0.16 (+0.15%) ▲|COST936.72-9.96 (-1.05%) ▼|CRM154.85-3.08 (-1.95%) ▼|CSCO118.13+0.43 (+0.36%) ▲|CVS103.39-0.20 (-0.19%) ▼|CVX167.77-0.70 (-0.42%) ▼|DE627.71+2.70 (+0.43%) ▲|DHR190.17-2.61 (-1.35%) ▼|DIS96.82-1.07 (-1.09%) ▼|DUK127.75-0.58 (-0.45%) ▼|EMR143.17+0.35 (+0.25%) ▲|FDX310.30-15.10 (-4.64%) ▼|GD352.36+4.29 (+1.23%) ▲|GE372.14-1.57 (-0.42%) ▼|GEV1,136.11+33.60 (+3.05%) ▲|GILD125.94-0.40 (-0.31%) ▼|GM76.24-1.10 (-1.42%) ▼|GOOG353.23+1.95 (+0.56%) ▲|GOOGL356.25+2.60 (+0.74%) ▲|GS1,012.12-8.09 (-0.79%) ▼|HD351.68+0.87 (+0.25%) ▲|HON223.56-4.24 (-1.86%) ▼|IBM277.94-0.06 (-0.02%) ▼|INTC139.67+7.95 (+6.04%) ▲|INTU261.85-4.55 (-1.71%) ▼|ISRG402.03-3.94 (-0.97%) ▼|JNJ255.29-3.23 (-1.25%) ▼|JPM327.51-1.88 (-0.57%) ▼|KO82.02-0.63 (-0.76%) ▼|LIN519.52+8.46 (+1.65%) ▲|LLY1,209.02-20.91 (-1.70%) ▼|LMT505.63+3.56 (+0.71%) ▲|LOW219.21-0.44 (-0.20%) ▼|LRCX426.47+15.56 (+3.79%) ▲|MA511.55+1.91 (+0.37%) ▲|MCD269.20+2.02 (+0.76%) ▲|MDLZ58.98-1.17 (-1.95%) ▼|MDT79.32-1.62 (-2.00%) ▼|META556.23-6.37 (-1.13%) ▼|MMM162.36-0.08 (-0.05%) ▼|MO72.57-1.48 (-2.00%) ▼|MRK128.35-1.03 (-0.80%) ▼|MS209.12-2.60 (-1.23%) ▼|MSFT370.29+1.72 (+0.47%) ▲|MU1,143.41-1.88 (-0.16%) ▼|NEE88.15-0.51 (-0.58%) ▼|NFLX72.68-1.11 (-1.50%) ▼|NKE41.04-0.45 (-1.07%) ▼|NOW97.61-2.37 (-2.37%) ▼|NVDA198.38+3.41 (+1.75%) ▲|ORCL145.41-2.36 (-1.59%) ▼|PEP136.34-2.34 (-1.69%) ▼|PFE24.08-0.29 (-1.19%) ▼|PG145.79-2.67 (-1.80%) ▼|PLTR116.87+1.17 (+1.01%) ▲|PM179.75-3.13 (-1.71%) ▼|QCOM186.61-2.11 (-1.12%) ▼|RTX188.55+1.22 (+0.65%) ▲|SBUX102.88-1.18 (-1.13%) ▼|SCHW92.47+1.92 (+2.12%) ▲|SO96.40-0.36 (-0.37%) ▼|SPG224.92-2.65 (-1.16%) ▼|T20.90-0.93 (-4.24%) ▼|TMO500.05-6.37 (-1.26%) ▼|TMUS168.85-5.12 (-2.94%) ▼|TSLA416.37+4.53 (+1.10%) ▲|TXN294.38+8.90 (+3.12%) ▲|UBER73.38-2.12 (-2.81%) ▼|UNH416.48-3.34 (-0.80%) ▼|UNP271.91-0.80 (-0.29%) ▼|UPS106.37-1.64 (-1.52%) ▼|USB60.54-0.22 (-0.36%) ▼|V342.68+1.03 (+0.30%) ▲|VZ42.78-1.32 (-2.99%) ▼|WFC82.82-0.69 (-0.83%) ▼|WMT113.63-0.98 (-0.85%) ▼|XOM136.10+0.04 (+0.03%) ▲|AAPL288.37+6.63 (+2.35%) ▲|ABBV252.55-1.76 (-0.69%) ▼|ABT91.62-1.09 (-1.18%) ▼|ACN123.89-0.85 (-0.68%) ▼|ADBE202.40-4.04 (-1.95%) ▼|AMAT730.21+35.57 (+5.12%) ▲|AMD572.95+33.46 (+6.20%) ▲|AMGN359.32-1.23 (-0.34%) ▼|AMT164.00-4.67 (-2.77%) ▼|AMZN239.47-0.67 (-0.28%) ▼|AVGO375.32+2.87 (+0.77%) ▲|AXP337.93-2.95 (-0.87%) ▼|BA216.73+2.04 (+0.95%) ▲|BAC57.02-0.87 (-1.49%) ▼|BKNG179.97-2.44 (-1.34%) ▼|BLK961.93+11.76 (+1.24%) ▲|BMY57.76-0.81 (-1.37%) ▼|BNY144.96+1.16 (+0.81%) ▲|BRK-B496.56+0.56 (+0.11%) ▲|C140.00-2.49 (-1.75%) ▼|CAT1,063.07+29.88 (+2.89%) ▲|CL91.95-0.46 (-0.49%) ▼|CMCSA24.54+0.32 (+1.30%) ▲|COF200.47-1.81 (-0.89%) ▼|COP104.36+0.16 (+0.15%) ▲|COST936.72-9.96 (-1.05%) ▼|CRM154.85-3.08 (-1.95%) ▼|CSCO118.13+0.43 (+0.36%) ▲|CVS103.39-0.20 (-0.19%) ▼|CVX167.77-0.70 (-0.42%) ▼|DE627.71+2.70 (+0.43%) ▲|DHR190.17-2.61 (-1.35%) ▼|DIS96.82-1.07 (-1.09%) ▼|DUK127.75-0.58 (-0.45%) ▼|EMR143.17+0.35 (+0.25%) ▲|FDX310.30-15.10 (-4.64%) ▼|GD352.36+4.29 (+1.23%) ▲|GE372.14-1.57 (-0.42%) ▼|GEV1,136.11+33.60 (+3.05%) ▲|GILD125.94-0.40 (-0.31%) ▼|GM76.24-1.10 (-1.42%) ▼|GOOG353.23+1.95 (+0.56%) ▲|GOOGL356.25+2.60 (+0.74%) ▲|GS1,012.12-8.09 (-0.79%) ▼|HD351.68+0.87 (+0.25%) ▲|HON223.56-4.24 (-1.86%) ▼|IBM277.94-0.06 (-0.02%) ▼|INTC139.67+7.95 (+6.04%) ▲|INTU261.85-4.55 (-1.71%) ▼|ISRG402.03-3.94 (-0.97%) ▼|JNJ255.29-3.23 (-1.25%) ▼|JPM327.51-1.88 (-0.57%) ▼|KO82.02-0.63 (-0.76%) ▼|LIN519.52+8.46 (+1.65%) ▲|LLY1,209.02-20.91 (-1.70%) ▼|LMT505.63+3.56 (+0.71%) ▲|LOW219.21-0.44 (-0.20%) ▼|LRCX426.47+15.56 (+3.79%) ▲|MA511.55+1.91 (+0.37%) ▲|MCD269.20+2.02 (+0.76%) ▲|MDLZ58.98-1.17 (-1.95%) ▼|MDT79.32-1.62 (-2.00%) ▼|META556.23-6.37 (-1.13%) ▼|MMM162.36-0.08 (-0.05%) ▼|MO72.57-1.48 (-2.00%) ▼|MRK128.35-1.03 (-0.80%) ▼|MS209.12-2.60 (-1.23%) ▼|MSFT370.29+1.72 (+0.47%) ▲|MU1,143.41-1.88 (-0.16%) ▼|NEE88.15-0.51 (-0.58%) ▼|NFLX72.68-1.11 (-1.50%) ▼|NKE41.04-0.45 (-1.07%) ▼|NOW97.61-2.37 (-2.37%) ▼|NVDA198.38+3.41 (+1.75%) ▲|ORCL145.41-2.36 (-1.59%) ▼|PEP136.34-2.34 (-1.69%) ▼|PFE24.08-0.29 (-1.19%) ▼|PG145.79-2.67 (-1.80%) ▼|PLTR116.87+1.17 (+1.01%) ▲|PM179.75-3.13 (-1.71%) ▼|QCOM186.61-2.11 (-1.12%) ▼|RTX188.55+1.22 (+0.65%) ▲|SBUX102.88-1.18 (-1.13%) ▼|SCHW92.47+1.92 (+2.12%) ▲|SO96.40-0.36 (-0.37%) ▼|SPG224.92-2.65 (-1.16%) ▼|T20.90-0.93 (-4.24%) ▼|TMO500.05-6.37 (-1.26%) ▼|TMUS168.85-5.12 (-2.94%) ▼|TSLA416.37+4.53 (+1.10%) ▲|TXN294.38+8.90 (+3.12%) ▲|UBER73.38-2.12 (-2.81%) ▼|UNH416.48-3.34 (-0.80%) ▼|UNP271.91-0.80 (-0.29%) ▼|UPS106.37-1.64 (-1.52%) ▼|USB60.54-0.22 (-0.36%) ▼|V342.68+1.03 (+0.30%) ▲|VZ42.78-1.32 (-2.99%) ▼|WFC82.82-0.69 (-0.83%) ▼|WMT113.63-0.98 (-0.85%) ▼|XOM136.10+0.04 (+0.03%) ▲|
32 C
New York
Tuesday, June 30, 2026

Tag: study

newssourceFORcompanyinformationcontent1releasesmarket

nubia Unveils Pad Pro, Designed for Work, Study and Entertainment

SHENZHEN, China, June 12, 2025 /PRNewswire/ -- nubia has launched its first-ever tablet - the nubia Pad Pro. Designed to meet the growing demands...

Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease

TAINAN, June 12, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel...

Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA’s 85th Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 12, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and...

PEPG Investor Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against PepGen Inc.

SAN DIEGO, June 12, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise...

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival.

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis...

4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment Landscape | DelveInsight

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation...

Cancer Pain Market Set to Transform by 2034 Due to Launch of Breakthrough Therapies | DelveInsight

According to DelveInsight's analysis, the growth of the cancer pain market is expected to be mainly driven by increasing incidence and advances in disease...

RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit

SAN DIEGO, June 12, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)...

[Latest] Global Pharmaceutical Glass Packaging Market Size/Share Worth USD 49.20 Billion by 2034 at a 7.87% CAGR: Business Research Industry (Analysis, Outlook, Leaders, Report,...

[220+ Pages Latest Report] According to a market research study published by Business Research Industry, the demand analysis of Global Pharmaceutical Glass Packaging Market size & share revenue was valued at approximately USD 23.36 Billion in 2024 and is expected to reach USD 24.87 Billion in 2025 and is expected to reach around USD 49.20 Billion by 2034, at a CAGR of 7.87% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Corning Incorporated, Nipro Corporation, SGD S.A., Stoelzle Oberglas GmbH, Bormioli Pharma S.p.A., West Pharmaceutical Services Inc., Schott AG, Gerresheimer AG, Shandong Medicinal Glass Co. Ltd., Beatson Clark, Ardagh Group S.A, Arab Pharmaceutical Glass Co., Piramal Enterprises Ltd., Şişecam Group, Owens-Illinois Inc., DWK Life sciences, and others. 
[220+ Pages Latest Report] According to a market research study published by Business Research Industry, the demand analysis of Global Pharmaceutical Glass Packaging Market size & share revenue was valued at approximately USD 23.36 Billion in 2024 and is expected to reach USD 24.87 Billion in 2025 and is expected to reach around USD 49.20 Billion by 2034, at a CAGR of 7.87% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Corning Incorporated, Nipro Corporation, SGD S.A., Stoelzle Oberglas GmbH, Bormioli Pharma S.p.A., West Pharmaceutical Services Inc., Schott AG, Gerresheimer AG, Shandong Medicinal Glass Co. Ltd., Beatson Clark, Ardagh Group S.A, Arab Pharmaceutical Glass Co., Piramal Enterprises Ltd., Şişecam Group, Owens-Illinois Inc., DWK Life sciences, and others.

Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU’s Committee for Veterinary Medicinal Products (CVMP)

Company expects approval and product supply in market before the end of third quarter GREENFIELD, Ind., June 12, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:...

DBV Technologies participera au prochain congrès EAACI 2025

Châtillon, France, le 12 juin (22:30 CEST) 2025

DBV Technologies to Participate in Upcoming EAACI Congress 2025

Châtillon, France, June 12, 2025

Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment

PARAMUS, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, announced today Gabrail Cancer Center (GCC) in Canton, Ohio is now activated and open for enrolling patients in its Phase 2a clinical trial evaluating their continuous low-dose lenalidomide, STAR-LLD, for the treatment of multiple myeloma (MM). Dr. Nash Gabrail, medical oncologist and founder of the Center, is the study’s lead investigator. Regional Medical Oncology Center, located in Wilson, NC, has also opened as the trial’s second active clinical site.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStudy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers